Integra LifeSciences Holdings Corporation (IART) vs. Its Peers Critical Review

Integra LifeSciences Holdings Corporation (NASDAQ: IART) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare Integra LifeSciences Holdings Corporation to similar companies based on the strength of its dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Insider and Institutional Ownership

84.9% of Integra LifeSciences Holdings Corporation shares are owned by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 21.5% of Integra LifeSciences Holdings Corporation shares are owned by insiders. Comparatively, 11.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Integra LifeSciences Holdings Corporation and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integra LifeSciences Holdings Corporation 0 4 6 0 2.60
Integra LifeSciences Holdings Corporation Competitors 181 1148 2513 89 2.64

Integra LifeSciences Holdings Corporation currently has a consensus target price of $53.11, suggesting a potential upside of 13.53%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.74%. Given Integra LifeSciences Holdings Corporation’s higher probable upside, research analysts clearly believe Integra LifeSciences Holdings Corporation is more favorable than its peers.

Volatility & Risk

Integra LifeSciences Holdings Corporation has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Integra LifeSciences Holdings Corporation’s peers have a beta of 1.06, suggesting that their average stock price is 6% more volatile than the S&P 500.

Profitability

This table compares Integra LifeSciences Holdings Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Integra LifeSciences Holdings Corporation 4.52% 16.35% 6.83%
Integra LifeSciences Holdings Corporation Competitors -126.42% -36.26% -9.90%

Valuation & Earnings

This table compares Integra LifeSciences Holdings Corporation and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Integra LifeSciences Holdings Corporation $1.05 billion $240.98 million 76.69
Integra LifeSciences Holdings Corporation Competitors $827.23 million $159.50 million 72.35

Integra LifeSciences Holdings Corporation has higher revenue and earnings than its peers. Integra LifeSciences Holdings Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Integra LifeSciences Holdings Corporation beats its peers on 8 of the 13 factors compared.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

What are top analysts saying about Integra LifeSciences Holdings Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Integra LifeSciences Holdings Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit